Robert Hershberg - 06 Oct 2026 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Reporting relationship: Director
Issuer ticker: RXRX
Reported as of: 06 Oct 2026
Net transaction value: -$125,000
SEC form: 4
Accepted by SEC: 07 Oct 2026, 18:08:23 UTC
Prior SEC filing: 11 Sep 2026
Next SEC filing: 16 Oct 2026
Source filing: View source filing
Reporting owner signature: /s/ Kyle Nelson, attorney-in-fact

Key filing fact

Robert Hershberg filed Form 4 for RECURSION PHARMACEUTICALS, INC. (RXRX) on 07 Oct 2026.

Key facts

This page summarizes Robert Hershberg's Form 4 filing for RECURSION PHARMACEUTICALS, INC. (RXRX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Oct 2026, 18:08.

Change

Previous filing in this sequence was filed on 11 Sep 2026.
Current net transaction value: -$125,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001274139 Primary reporting owner

HERSHBERG ROBERT

Relationship: Director
Address: C/O RECURSION PHARMACEUTICALS, 41 S. RIO GRANDE STREET, SALT LAKE CITY
Signature: /s/ Kyle Nelson, attorney-in-fact
Signature date: 07 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RXRX transaction

Class A Common Stock

Options Exercise

Transaction value
Shares: +25,000
Change %: +15%
Price: $2.22^*
Shares after: 187,156
Date: 06 Oct 2026
Ownership: Direct
Footnotes: F1

RXRX transaction

Class A Common Stock

Sale

Transaction value: $125,000
Shares: -25,000
Change %: -13%
Price: $5.00
Shares after: 162,156
Date: 06 Oct 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RXRX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -25,000
Change %: -4.8%
Price: $2.22^*
Shares after: 500,000
Date: 06 Oct 2026
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 25,000
Exercise price: $2.22
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

This transaction is pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 17, 2025.

Footnote F2

One forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 16, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date. Date exercisable varies by tranche.